



Buenos Aires, July 11, 2016

Conflict-of-interest disclosure:

Ricardo A. López and Jorge Zorzopulos are shear holders of Immunotech S.A. the company that provided funding for several of the studies partially described in the review entitled "Immunomodulatory Oligonucleotide IMT504: Effects on Mesenchymal Stem Cells as a First-in-Class Immunoprotective/ Immunoregenerative Therapy" submitted to the World Journal of Stem Cells for consideration for publication.

A handwritten signature consisting of stylized, overlapping letters, likely 'JZ', in black ink.

Jorge Zorzopulos

A handwritten signature in black ink, appearing to be 'RAL', with a long horizontal flourish extending to the right.

Ricardo A. López

Conflicts of interest disclosure:

David Horn, LLC has ownership rights regarding patent rights of IMT504. David Horn has ownership rights of David Horn, LLC, Mid-Atlantic BioTherapeutics, Inc. and Prosper Animal Health.

A handwritten signature in black ink, appearing to read 'David Horn', written in a cursive style.

David Horn, MD.